Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 25Other hematologic neoplasm 19Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × blinatumomab × Myeloid × Clear all
NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Ascentage Pharma Group Inc.

Phase 1 Recruiting
242 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡